This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Canopy Growth Corporation (CGC) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
The latest trading day saw Canopy Growth Corporation (CGC) settling at $10.24, representing a -0.97% change from its previous close.
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Do Options Traders Know Something About Canopy Growth (CGC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
Canopy Growth Corporation (CGC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $4.79, moving -0.83% from the previous trading session.
ResMed (RMD) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 3.87% and 0.46%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) reachead $4.41 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Canopy Growth Corporation (CGC) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the most recent trading session, Canopy Growth Corporation (CGC) closed at $4.56, indicating a -0.87% shift from the previous trading day.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw Canopy Growth Corporation (CGC) settling at $4.86, representing a +1.46% change from its previous close.
Zacks Market Edge Highlights: Canopy Growth, Tilray Brands, Constellation Brands, Innovative Industrial Properties and Jazz Pharmaceuticals
by Zacks Equity Research
Canopy Growth, Tilray Brands, Constellation Brands, Innovative Industrial Properties and Jazz Pharmaceuticals are part of the Zacks Market Edge blog.
Pot Stocks: Values or Traps?
by Tracey Ryniec
Pot stocks used to be hot but many have plunged over the last 2 years. Are there deals?
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
What's in Store for Canopy Growth (CGC) in Q2 Earnings?
by Zacks Equity Research
In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business.
Here's Why Canopy Growth Corporation (CGC) Fell More Than Broader Market
by Zacks Equity Research
In the closing of the recent trading day, Canopy Growth Corporation (CGC) stood at $0.51, denoting a -1.03% change from the preceding trading day.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and latest launches.
Zacks Investment Ideas feature highlights: Canopy Growth, Green Thumb Industries, Tilray Brands and Innovative Industrial Properties
by Zacks Equity Research
Canopy Growth, Green Thumb Industries, Tilray Brands and Innovative Industrial Properties are part of the Zacks Investment Ideas article.
3 Cannabis Stocks Soaring on HHS' Recommendation to DEA
by Abhinab Dasgupta
Canopy Growth (CGC), Tilray (TLRY) and Cronos (CRON) shoot up on news that the DEA is considering recommendations for low-risk reclassification of marijuana.
Time to Get High on Pot Stocks? (3 Catalysts)
by Andrew Rocco
When it comes to marijuana, a significant disconnect exists between the US government and the American people. Stock Strategist Andrew Rocco explains why the worst may be over for marijuana investors.
Canopy Growth Corporation (CGC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of 60% and 16.19%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 14.04% and 6.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Baxter International (BAX) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of -6.78% and 2.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Canopy Growth (CGC) in Q1 Earnings?
by Zacks Equity Research
Strong demand for legal cannabis products in the Canadian recreational cannabis market and the launch of new products are expected to have driven Canopy Growth's (CGC) Q1 performance.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $0.39, marking a -0.85% move from the previous day.
Canopy Growth (CGC) Improves Liquidity With Another Selloff
by Zacks Equity Research
Canopy Growth's (CGC) decision to divest facilities aligns with its organizational transformation plan.
Rockwell Medical (RMTI) Soars 20.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Rockwell Medical (RMTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.